The FDA has announced proposals intended to bolster domestic drug manufacturing, aligning with the president's budgetary plans.
These initiatives are part of a broader effort to enhance local manufacturing capabilities in the pharmaceutical sector.
The initiative aligns with ongoing efforts to reduce reliance on foreign production and improve the responsiveness of domestic facilities.